Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px
Document › Details

Proteros Biostructures GmbH. (5/6/13). "Press Release: Proteros and Eisai Achieve Target in Lead Discovery Project, Delivering Kinetically Optimized Lead Compounds". Martinsried.

Organisations Organisation Proteros Biostructures GmbH
  Group Proteros (Group)
  Organisation 2 Eisai Co., Ltd.
  Group Eisai (Group)
Products Product structure-based drug design
  Product 2 lead generation (service)
Person Person Neumann, Lars (Proteros 201305 VP Discovery Projects + Project Manager)
     


Proteros biostructures GmbH today announced the successful completion of an integrated lead discovery collaboration with Eisai Co., Ltd. Based on Proteros' structure guided discovery platform, various series of Lead Compounds were developed within a period of 10 months.

The developed compound series showed single digit nanomolar Kd values, as well as optimized binding kinetics and kinetic selectivity. Hits were identified out of the Proteros fragment library and the optimization process was driven by high quality protein crystallography as well as kinetic and thermodynamic profiling and the seamless interactions between Eisai and Proteros medicinal and computational chemists.

Dr. Lars Neumann, Vice President Discovery Projects and Project Manager stated: "We are very satisfied with the course of the project and are pleased to deliver the lead compound series to our partner Eisai Co., Ltd. We look forward to contributing further to the success of the Eisai research pipeline using our unique technology platform."


About Proteros:

Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery. Proteros uses its technical expertise, industrial processes and unique technologies for crystallography, kinetic and thermodynamic profiling and fragment-based lead discovery. The platform allows structure accelerated Lead Discovery. Proteros currently provides services to more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia.


About Eisai:

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com/.


Contact:

Proteros biostructures GmbH
Dr. Lars Neumann
Bunsenstrasse 7a
82152 Martinsried
Germany
Phone: +49 89 7007 61 - 0
E-Mail: business@proteros.com
Internet: www.proteros.com

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Proteros (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top